<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027794</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-30001</org_study_id>
    <secondary_id>EORTC-30001</secondary_id>
    <nct_id>NCT00027794</nct_id>
  </id_info>
  <brief_title>Radical Prostatectomy in Treating Patients With Locally Advanced Prostate Cancer</brief_title>
  <official_title>Radical Prostatectomy for Locally Advanced Prostate Cancer. A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radical prostatectomy may be an effective treatment for locally advanced prostate&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of radical prostatectomy in treating&#xD;
      patients who have locally advanced prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the success rate of radical prostatectomy in patients with locally advanced&#xD;
           adenocarcinoma of the prostate.&#xD;
&#xD;
        -  Determine the serious toxic event rate of this surgery in these patients.&#xD;
&#xD;
        -  Determine the pN status of patients treated with this surgery.&#xD;
&#xD;
        -  Determine the percentage of patients found to have organ-confined tumors (pT2) after&#xD;
           undergoing this surgery.&#xD;
&#xD;
        -  Determine the 2-year prostate-specific antigen-free survival rate of patients treated&#xD;
           with this surgery.&#xD;
&#xD;
        -  Determine the surgical morbidity rates of patients treated with this surgery.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients undergo limited pelvic lymphadenectomy and then radical retropubic prostatectomy.&#xD;
&#xD;
      Patients who are found to have pN-positive disease receive further treatment according to the&#xD;
      investigator's discretion. Patients with pN0 disease are followed every 3 months for 1 year&#xD;
      and then every 4 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 32-74 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">40</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Unilateral cT3a, cN0, M0&#xD;
&#xD;
          -  Well or moderately differentiated tumor&#xD;
&#xD;
               -  Gleason score no greater than 7 (4 plus 3 or 3 plus 4)&#xD;
&#xD;
          -  Total serum prostate-specific antigen no greater than 20 ng/mL (Hybritech equivalent)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  70 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 9 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times normal&#xD;
&#xD;
          -  ALT or AST less than 3 times normal&#xD;
&#xD;
          -  PT and PTT normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No preexisting uncontrolled cardiac disease, signs of cardiac failure, or rhythm&#xD;
             disturbances requiring therapy&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No gross abnormalities on chest x-ray&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other disease that would preclude surgery&#xD;
&#xD;
          -  No other prior malignancy except adequately treated basal cell skin cancer&#xD;
&#xD;
          -  No other concurrent primary malignancy&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No prior hormonal therapy that would affect assessment of clinical T staging, margin&#xD;
             positivity, or definitive pT staging&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior pelvic radiotherapy that would affect surgical resectability and&#xD;
             perioperative morbidity&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No prior surgery in the small pelvis (vascular surgery, mesh graft hernia repair, any&#xD;
             surgery for benign prostatic hypertrophy, or transurethral resection of prostate) that&#xD;
             would preclude prostatectomy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hein van Poppel, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Gasthuisberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virga Jesse Hospital</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico H. San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Faculty Hospital</name>
      <address>
        <city>Martin</city>
        <zip>03659</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Slovakia</country>
  </location_countries>
  <results_reference>
    <citation>Van Poppel H, Vekemans K, Da Pozzo L, Bono A, Kliment J, Montironi R, Debois M, Collette L. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer. 2006 May;42(8):1062-7. Epub 2006 Apr 18.</citation>
    <PMID>16624554</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

